|
Jul 29
|
Why Repligen (RGEN) Stock Is Up Today
|
|
Jul 29
|
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
|
|
Jul 29
|
Repligen: Q2 Earnings Snapshot
|
|
Jul 29
|
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
|
|
Jul 28
|
Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings
|
|
Jul 22
|
Netflix downgraded, Intel initiated: Wall Street's top analyst calls
|
|
Jul 21
|
Here's Why Repligen (RGEN) is a Strong Growth Stock
|
|
Jul 18
|
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know
|
|
Jul 18
|
3 Reasons RGEN is Risky and 1 Stock to Buy Instead
|
|
Jul 17
|
Repligen to Report Second Quarter 2025 Financial Results
|
|
Jun 10
|
1 Unprofitable Stock for Long-Term Investors and 2 to Ignore
|
|
May 12
|
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
|
|
Mar 26
|
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
|
|
Mar 25
|
Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?
|
|
Mar 12
|
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
|
|
Mar 11
|
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
|
|
Feb 21
|
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
|
|
Feb 21
|
Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
|
Feb 21
|
Q4 2024 Repligen Corp Earnings Call
|
|
Feb 20
|
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
|